Lista de obras - Giuseppe Tambussi - Dominio Público Uruguay

A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses

artículo científico publicado en 2011

Access denied? The status of co-receptor inhibition to counter HIV entry

artículo científico publicado en 2007

Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection

artículo científico publicado en 2007

B-cell subset alterations and correlated factors in HIV-1 infection

artículo científico publicado en 2013

Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets

artículo científico publicado en 2015

Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection

artículo científico publicado en 2016

Calcitonin gene-related peptide inhibits Langerhans cell-mediated HIV-1 transmission

artículo científico publicado en 2013

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden

artículo científico publicado en 2011

Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial

artículo científico

Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance

artículo científico publicado en 2002

Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy.

artículo científico publicado en 2006

Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine

artículo científico publicado en 2011

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy

artículo científico publicado en 2013

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy

artículo científico publicado en 2015

Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response

artículo científico publicado en 2017

Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.

artículo científico publicado en 2016

Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection

artículo científico publicado en 2014

Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine

artículo científico publicado en 2014

GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study

artículo científico publicado en 2005

HHV-8 DNA replication correlates with the clinical status in AIDS-related Kaposi's sarcoma

artículo científico publicado en 2016

HIV-1 DNA predicts disease progression and post-treatment virological control

artículo científico publicado en 2014

Immunological recovery after 24 weeks of antiretroviral therapy in patients with X4 virus during primary HIV infection

artículo científico publicado en 2014

Immunosenescence and hurdles in the clinical management of older HIV-patients

artículo científico publicado en 2017

Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection

artículo científico publicado en 2005

Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals

artículo científico publicado en 2011

Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression

artículo científico publicado en 2014

Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy

artículo científico publicado en 2002

Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients

artículo científico publicado en 2012

Life expectancy in the immune recovery era: the evolving scenario of the HIV epidemic in northern Italy

artículo científico

Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up

artículo científico publicado en 2016

NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain

artículo científico publicado en 2002

Nitric oxide production in HIV-1 infected patients receiving intermittent cycles of interleukin-2 and antiretrovirals

artículo científico publicado en 2004

Optimal use of maraviroc in clinical practice

artículo científico publicado en 2008

Oral CCR5 inhibitors: will they make it through?

artículo científico publicado en 2006

Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients

artículo científico publicado en 2015

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection

artículo científico publicado en 2012

Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers

artículo científico publicado en 2013

Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males

artículo científico publicado en 2017

Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions

artículo científico publicado en 2005

Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort

artículo científico publicado en 2017

Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

artículo científico publicado en 2010

Risk of cancers during interrupted antiretroviral therapy in the SMART study

artículo científico publicado en 2007

Short-course antiretroviral therapy in primary HIV infection

artículo científico publicado en 2013

The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels

artículo científico publicado en 2015

The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.

artículo científico publicado en 2008

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

artículo científico publicado en 2010

The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study

artículo científico publicado en 2014

The preventive phase I trial with the HIV-1 Tat-based vaccine

artículo científico

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART

artículo científico publicado en 2010

Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial

artículo científico publicado en 2016

Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy

artículo científico publicado en 2002

Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2.

artículo científico publicado en 2002

Virological responses in a patient with recent HIV-1 infection experiencing an EBV reactivation

artículo científico publicado en 2007

Lista de obras de Giuseppe Tambussi

A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses

Access denied? The status of co-receptor inhibition to counter HIV entry

Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection

B-cell subset alterations and correlated factors in HIV-1 infection

Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets

Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection

Calcitonin gene-related peptide inhibits Langerhans cell-mediated HIV-1 transmission

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden

Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial

Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance

Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy.

Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy

Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response

Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.

Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection

Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine

GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study

HHV-8 DNA replication correlates with the clinical status in AIDS-related Kaposi's sarcoma

HIV-1 DNA predicts disease progression and post-treatment virological control

Immunological recovery after 24 weeks of antiretroviral therapy in patients with X4 virus during primary HIV infection

Immunosenescence and hurdles in the clinical management of older HIV-patients

Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection

Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals

Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression

Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy

Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients

Life expectancy in the immune recovery era: the evolving scenario of the HIV epidemic in northern Italy

Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up

NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain

Nitric oxide production in HIV-1 infected patients receiving intermittent cycles of interleukin-2 and antiretrovirals

Optimal use of maraviroc in clinical practice

Oral CCR5 inhibitors: will they make it through?

Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection

Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers

Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males

Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions

Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort

Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

Risk of cancers during interrupted antiretroviral therapy in the SMART study

Short-course antiretroviral therapy in primary HIV infection

The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels

The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study

The preventive phase I trial with the HIV-1 Tat-based vaccine

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART

Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial

Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy

Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2.

Virological responses in a patient with recent HIV-1 infection experiencing an EBV reactivation